Preimplantation genetic testing and chances of a healthy live birth amongst recipients of fresh donor oocytes in the Uni
- PDF / 383,059 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 79 Downloads / 176 Views
ASSISTED REPRODUCTION TECHNOLOGIES
Preimplantation genetic testing and chances of a healthy live birth amongst recipients of fresh donor oocytes in the United States Cassandra Roeca 1
&
Rachel Johnson 2 & Nichole Carlson 2 & Alex J Polotsky 1
Received: 30 April 2020 / Accepted: 25 June 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Purpose To evaluate if preimplantation genetic testing (PGT) improves the odds of a healthy live birth amongst recipients of fresh donor oocytes. Methods We performed a retrospective cohort study including in vitro fertilization cycles of women using fresh donor oocytes reported to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System, between 2013 and 2015. Cycles were categorized based on PGT. Primary outcome measure was a good birth outcome (GBO), defined as a singleton, term, live birth with an average birthweight. Multivariable generalized estimating equation models were fit to analyze the effect of PGT. Interaction effect between cycle type (fresh vs frozen) and PGT was tested. Results Of 28,153 included cycles, 3708 had PGT while 24,445 did not. PGT cycles were less likely to result in an embryo transfer (ET) (64 vs 94%), but were associated with increased rates of frozen ET (70 vs 41%), single ET (67 vs 44%), and blastocyst ET (87 vs 65%). There was a significant interaction between PGT and cycle type. Cycles using PGT increased the probability of a GBO 12% in frozen cycles (RR 1.12; 95% CI 1.02, 1.22; p = 0.018), but PGT was detrimental to success in fresh cycles with a 53% reduced likelihood of GBO (RR 0.47; 9% CI 0.41, 0.54; p < 0.001). Conclusion PGT, as practiced during the most recently available national data in women using fresh donor oocytes, was associated with increased probability of a healthy live birth amongst frozen cycles, but was not beneficial in fresh cycles. Keywords Preimplantation genetic testing . Embryo transfer . Donor oocyte . In vitro fertilization . Good birth outcome
Introduction
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10815-020-01874-8) contains supplementary material, which is available to authorized users.
advanced maternal age (AMA) [2, 3]. In patients who are not AMA, there is no clear benefit of PGT-A on in vitro fertilization (IVF) outcomes [4]. In donor oocyte IVF cycles, donors are typically in their 20s and early 30s, and thus, the prevalence of aneuploidy is expected to be lower than for infertility patients undergoing autologous oocytes [5]. To date, available national evidence suggests that PGT is associated with lower odds of live birth amongst donor oocyte cycles in the USA through 2013 [6]. Outcomes reflective of more current practice, including trophectoderm biopsy, PGT platforms, and vitrification, are lacking. We sought to evaluate the effect of PGT on assisted reproductive technology (ART) outcomes for fresh donor oocyte recipients in a more contemporary setting.
* Cassandra Roeca Cassandra.roeca@cuanschutz
Data Loading...
